Skip to content
OpenCapital
Get started

Lifecore Biomedical, Inc. LFCR Cash Provided by (Used in) Investing Activity, Including Discontinued Operation

Cash Provided by (Used in) Investing Activity, Including Discontinued Operation at other companies

Baxter International logo
Baxter InternationalBAX
-$133M-104%
ADMA Biologics logo
ADMA BiologicsADMA
$2.4M+151%
Charles River Laboratories logo
Charles River LaboratoriesCRL
-$407.85M-797%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
-$268.65M-1,092%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
——
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
——

Other financials

Income statement

See full
Revenue$23.2M-36.4%
Gross profit$4.5M-68.1%
Operating income-$4.7M—
Net income-$15.0M-1,206%
EPS (diluted)-$0.43-1,333%

Balance sheet

See full
Cash & equivalents$20.8M+152%
Total debt$156.9M+1,310%
Total equity-$28.4M-2,229%
Total assets$225.5M-5.8%

Cash flow

See full
Operating cash flow$4.7M—
CapEx$1.1M-46.7%
Free cash flow$3.6M—

Valuation

See full
Market cap$196.92M-35.4%
Enterprise value$333.06M+8.3%
P/S1.6×+0.5×

Profitability

See full
Gross margin31.3%-1.4pp
Operating margin-14.5%-2.2pp
Net margin-30%—
FCF margin-36.4%—

Returns & leverage

See full
Return on equity-612.1%—
Debt / equity8.3×-1.5×
Current ratio3.8×+0.9×

Where this comes from

Reported directly by Lifecore Biomedical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Lifecore Biomedical, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lifecore Biomedical, Inc.'s cash provided by (used in) investing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lifecore Biomedical, Inc.'s cash provided by (used in) investing activity, including discontinued operation?
Lifecore Biomedical, Inc. (LFCR) reported cash provided by (used in) investing activity, including discontinued operation of -$1.12M in Q1 2026.
How has Lifecore Biomedical, Inc.'s cash provided by (used in) investing activity, including discontinued operation changed year-over-year?
Lifecore Biomedical, Inc.'s cash provided by (used in) investing activity, including discontinued operation increased by 46.7% year-over-year, from -$2.1M to -$1.12M.
What is the long-term trend for Lifecore Biomedical, Inc.'s cash provided by (used in) investing activity, including discontinued operation?
Over 2 years (2023 to 2025), Lifecore Biomedical, Inc.'s cash provided by (used in) investing activity, including discontinued operation has grown at a 50.8% compound annual growth rate (CAGR), from -$2.82M to -$6.42M.
What does cash provided by (used in) investing activity, including discontinued operation mean?
The total net cash flow resulting from all investing activities, including capital expenditures, acquisitions, and the purchase or sale of securities. It serves as a primary indicator of how much capital the company is reinvesting into its long-term growth and asset base.